| Summary: | 碩士 === 國立政治大學 === 科技管理與智慧財產研究所 === 105 === Tens of billions of dollars in large transactions shows that M&As are one of the most important strategies for pharmaceutical and the biotechnology industry to gain access to valuable technological resources in recent years. Nowadays, the challenges of pharmaceutical company include the growth rate of R&D cost were higher than sales, new drugs development were slower than industry demand, licensing from other company and high profit patent drugs turned into generics, which facing the threat from other competitors.
The development of pharmaceutical company becoming more concentrated that the top ten pharmaceutics account for half of the global sales. Moreover, with the growing demand from the health care, aging and novel therapeutics and under the threatens of health insurance payment and patent cliff, the tide of M&As for pharmaceutical and biotech companies will not decline. The purpose of M&A activities from the global top pharmaceutical companies, is to obtaining innovative technology and different types of biotechnology company. However, large R&D expenditure and high risk product development result in capital shortage problems. The abundant working capital and well-experienced manufacture, marketing and sales characteristics of big pharma enable the M&As of pharma and biotech arise.
The M&A strategic planning of acquiring intellectual property rights of the leading pharmaceutical company was investigated in this study. The background of Pfizer, its M&A process, strategies, product matrix, R&D and intellectual property-oriented discussion were examined. Therefore, this study may fulfill and provide some suggestions and references for further pharmaceutical and biotech M&A activities in Taiwanese biotechnology companies such as JHL. Except for seeking IPO as the only growing strategy, through M&A is another way to accelerate the development of Taiwan's biotechnology R&D and manufacturing ability to the international level.
|
|---|
